![Retapamulin Catalog No.:M10666-10 [3] Bepotastine (100 μM) dose-dependently](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M10666_1621562263.gif?v=1621562265)
Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
[3] Bepotastine (100 μM) dose-dependently inhibits chemotaxis of cultured guinea pig peritoneal eosinophils induced by LTB4
Khojasteh SC
PubMed PMID: 10576651
Smiles: CC1=CC=C(C=N1)C1=NC=C(Cl)C=C1C1C=CC(=CC=1)S(C)(=O)=O
Right now it is in phase I clinical trials for patients with refractory advanced solid tumors
Retapamulin Catalog No.:M10666-10 [3] Bepotastine (100 μM) dose-dependentlyRetapamulin, also known as SB 275833, is a newer topical agent of pleuromutilin class approved by the Food and Drug Administration for treatment of impetigo in children. It has been demonstrated to have low potential for the development of antibacterial resistance and a high degree of potency against poly drug resistant Gram positive bacteria found in skin infections including Staphylococcus aureus strains. The drug is safe owing to low systemic
US$ 99.95
US$ 42.95
US$ 42.95
US$ 19.95